Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 11fludarabine phosphate 10Rituximab 6Peripheral Blood Stem Cell Transplantation 6Cytarabine 6fludarabine 5Vincristine 4Radiotherapy 4Etoposide 4Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Filgrastim 3tisagenlecleucel 2blinatumomab 2Vorinostat 2Prednisone 2Pentetic Acid 2Methylprednisolone 2Melphalan 2Drug Therapy 2Doxorubicin 2Cord Blood Stem Cell Transplantation 2Carmustine 2CT-P10 2Busulfan 2Bortezomib 2Biopsy 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Burkitt Lymphoma × Leyk × Clear all
NCT02538926 2018-11-14

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

University of Washington

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡